Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
News|Articles|October 1, 2011
FDA Pipeline Preview, October 2011 (Janssen Biotech, GlaxoSmithKline, Pfizer, Johnson & Johnson, Bayer AG, ApoPharma, BTG, Chelsea Therapeutics, QLT, Neuraltus Pharmaceuticals, Accentia, 4SC, Tarix Pharmaceuticals)
Recent FDA action (through September 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001, cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
Advertisement
Complete response
Recommendations for approval
Fast-track designations
Orphan drug designations
Advertisement
Related to this article
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.
The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
Christopher Stanley, M.D., MBA, on the early population health wins of Henry Ford Health's Populance
Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
Christopher Stanley, M.D., MBA, on the early population health wins of Henry Ford Health's Populance
3
Christopher Stanley, M.D., MBA, on why Henry Ford Health's Populance is pivoting inward
4
On Populance's pivot to internal customers, some early wins and the current state of value-based care | A conversation with Christopher Stanley, M.D.. MBA
5